Company intelligence / Profile preview

MigVax

Kiryat Shmona, Israel

Ownership: Private
Development stage: Other

Overview

MigVax is developing MIGVAX-101, an oral subunit SARS‑CoV‑2 vaccine based on chimeric recombinant proteins designed from epitopes of IBV, MERS, SARS-CoV and SARS‑CoV‑2, aiming to induce mucosal, systemic, and cellular immunity; published preclinical data report induction of neutralizing IgG and IgA and cellular responses in animals and boosting of responses primed by an injected vaccine, but no human clinical trial data are publicly reported yet.[1][2]

Therapeutic areas: Infectious Diseases
Modalities: VaccineProteinRecombinant protein
Industry: Biotech

Drug pipeline

1 asset

MigVax-101

Preclinical

Partnerships

Migal Galilee Research Institute (technology and research origin, affiliate relationship)[1][4]

Beyond the preview

Go deeper on MigVax.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MigVax.

Explore the full profile